Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q2

9776.TEDINET S100S73T
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥9.9bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥20.1bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥10.0bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥291m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥493m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥296m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥589m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥386m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥508m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥226m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥569m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥258m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥226m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥319m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥16.7bnat 2023-09-30Cons.Assets
Total assets¥16.5bnat 2023-03-31Cons.Assets
Total assets¥16.2bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥5.7bnat 2023-09-30Cons.Liabilities
Total liabilities¥5.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥11.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥10.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥10.5bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥4.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.7bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥4.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥810m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥674m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥171m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥409m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥292m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥238m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥348m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥223m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥67.942023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥66.232023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥170.532022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥77.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥54.092022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio64.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio64.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.2%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥58m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥56m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥41m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥78m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥377m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥798m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥492m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥306m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7m
—segment totalrevenue2023-04-01 → 2023-09-30¥10.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥9.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥306m
—segment totalsegment profit2023-04-01 → 2023-09-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥10.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥308m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥489m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥46m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥30m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥371m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥356m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥805m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥472m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥333m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥6m
—segment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥9.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥333m
—segment totalsegment profit2022-04-01 → 2022-09-30¥721m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥10.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥334m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥751m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 549
ItemContextValueUnit
Other ioaPrior1YearInstant223373000JPY
Other ioaCurrentQuarterInstant203363000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-16841000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-22632000JPY
Investments and other assetsPrior1YearInstant671426000JPY
Investments and other assetsCurrentQuarterInstant668420000JPY
Noncurrent assetsPrior1YearInstant9210395000JPY
Noncurrent assetsCurrentQuarterInstant9004234000JPY
AssetsPrior1YearInstant16521281000JPY
AssetsCurrentQuarterInstant16712144000JPY
Notes and accounts payable tradePrior1YearInstant2179195000JPY
Notes and accounts payable tradeCurrentQuarterInstant2207092000JPY
Current portion of long term loans payablePrior1YearInstant133692000JPY
Current portion of long term loans payableCurrentQuarterInstant135367000JPY
Lease obligations clPrior1YearInstant127602000JPY
Lease obligations clCurrentQuarterInstant123776000JPY
Income taxes payablePrior1YearInstant89644000JPY
Income taxes payableCurrentQuarterInstant183549000JPY
Provision for bonusesPrior1YearInstant125073000JPY
Provision for bonusesCurrentQuarterInstant254614000JPY
Accounts payable otherPrior1YearInstant303901000JPY
Accounts payable otherCurrentQuarterInstant198868000JPY
Asset retirement obligations clPrior1YearInstant－JPY
Asset retirement obligations clCurrentQuarterInstant10000000JPY
Other clPrior1YearInstant297404000JPY
Other clCurrentQuarterInstant285223000JPY
Current liabilitiesPrior1YearInstant3256514000JPY
Current liabilitiesCurrentQuarterInstant3398492000JPY
Long term loans payablePrior1YearInstant1598629000JPY
Long term loans payableCurrentQuarterInstant1531783000JPY
Lease obligations nclPrior1YearInstant569426000JPY
Lease obligations nclCurrentQuarterInstant508967000JPY
Provision for directors retirement benefitsPrior1YearInstant69592000JPY
Provision for directors retirement benefitsCurrentQuarterInstant65500000JPY
Net defined benefit liabilityPrior1YearInstant18639000JPY
Net defined benefit liabilityCurrentQuarterInstant20822000JPY
Long term accounts payable otherPrior1YearInstant90414000JPY
Long term accounts payable otherCurrentQuarterInstant86614000JPY
Deferred tax liabilitiesPrior1YearInstant16594000JPY
Deferred tax liabilitiesCurrentQuarterInstant11859000JPY
Other nclPrior1YearInstant20483000JPY
Other nclCurrentQuarterInstant63953000JPY
Noncurrent liabilitiesPrior1YearInstant2383779000JPY
Noncurrent liabilitiesCurrentQuarterInstant2289500000JPY
LiabilitiesPrior1YearInstant5640294000JPY
LiabilitiesCurrentQuarterInstant5687992000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentQuarterInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentQuarterInstant1015270000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass